| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/30/2006 | WO2006033942A2 Pik4ca as modifier of the rac pathway and methods of use |
| 03/30/2006 | WO2006033912A2 Treatment of bone disorders with skeletal anabolic drugs |
| 03/30/2006 | WO2006033878A1 Process for preparing macrocyclic hcv protease inhibitors |
| 03/30/2006 | WO2006033851A1 Ring-closing metathesis process in supercritical fluid |
| 03/30/2006 | WO2006033698A2 Tissue matrix system |
| 03/30/2006 | WO2006033665A1 Tat-based vaccine compositions and methods of making and using same |
| 03/30/2006 | WO2006033604A1 A metered medication dose |
| 03/30/2006 | WO2006033481A1 Soluble toll-like receptor 4 protein |
| 03/30/2006 | WO2006033473A1 Denatured silk and aqueous extract thereof |
| 03/30/2006 | WO2006033453A1 Activity enhancer for interferon agent |
| 03/30/2006 | WO2006033433A1 Wound remedy |
| 03/30/2006 | WO2006033349A1 Total enteral nutritious composition |
| 03/30/2006 | WO2006033287A1 PHARMACEUTICAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR AND GLUTATHIONE |
| 03/30/2006 | WO2006032923A2 Inhibitors of protein kinase a anchoring |
| 03/30/2006 | WO2006032909A2 Pka ii anchoring disruption polypeptide |
| 03/30/2006 | WO2006032781A2 Peptide derivatives, compositions and uses in therapeutic treatment of herpesvirus infection |
| 03/30/2006 | WO2006032697A2 MODIFIED VPl-CAPSID PROTEIN OF PARVOVIRUS B19 |
| 03/30/2006 | WO2006032693A1 Intestinal epithelial glucose sensor |
| 03/30/2006 | WO2006032525A2 Combinational therapy for treating cancer |
| 03/30/2006 | WO2006032330A1 Annexin modulation and resistance to infection |
| 03/30/2006 | WO2006032245A1 Pharmaceutical active ingredient against hiv - syndrome |
| 03/30/2006 | WO2006032216A2 Peptides and apl-type derivatives of hsp60 and pharmaceutical compositions |
| 03/30/2006 | WO2006020581A9 Prevention and treatment of synucleinopathic and amyloidogenic disease |
| 03/30/2006 | WO2006012586A9 Modulation of fiaf and the gastrointestinal microbiota |
| 03/30/2006 | WO2006010499A3 Diagnostics and therapeutics for diseases associated with carboxypeptidase a2 (cpa2) |
| 03/30/2006 | WO2006008142A8 Diagnosis and therapy of psoriasis vulgaris |
| 03/30/2006 | WO2006005460A3 Diagnostics and therapeutics for diseases associated with nuclear receptor subfamily 2, group e, member 1 (nr2e1) |
| 03/30/2006 | WO2006001832A3 Selective incorporation of 5-hyroxytryptophan into proteins in mammalian cells |
| 03/30/2006 | WO2005123132A3 Use of liver-selective glucokinase activators |
| 03/30/2006 | WO2005121169A3 Apoptosis-inducing polypeptides |
| 03/30/2006 | WO2005107802A3 Method and system to remove soluble tnfr1, tnfr2, and il2 in patients |
| 03/30/2006 | WO2005105827A3 Compounds for proteasome enzyme inhibition |
| 03/30/2006 | WO2005103710A3 Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 1 (crhr1) |
| 03/30/2006 | WO2005099745A3 Gcp-170 fusion proteins and uses thereof |
| 03/30/2006 | WO2005098435A3 Peptides and peptidomimetics binding to cd23 |
| 03/30/2006 | WO2005097172A3 Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment |
| 03/30/2006 | WO2005090995A3 Method for the detection of autoantibodies against specific peptides and its use in diagnosis and treatment of pregnancy-loss or infertility |
| 03/30/2006 | WO2005082076A3 Methods for treating breast cancer using nrif3 related molecules |
| 03/30/2006 | WO2005071093A3 Chimpanzee adenovirus vaccine carriers |
| 03/30/2006 | WO2005068494A3 Chimera botulinum toxin type e |
| 03/30/2006 | WO2005056795A3 Hif oligonucleotide decoy molecules |
| 03/30/2006 | WO2005048993A3 Minimization of drug oxidation in drug irradiated excipients formulations |
| 03/30/2006 | WO2005048942A3 Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent |
| 03/30/2006 | WO2005035717A3 Process for the synchronization of ovulation for timed breeding without heat detection |
| 03/30/2006 | WO2004089297A3 Compounds and methods for treatment of thrombosis |
| 03/30/2006 | WO2004070012A3 Cell-killing molecules and methods of use thereof |
| 03/30/2006 | WO2004037196A3 Cytomodulating peptides and methods for treating neurological disorders |
| 03/30/2006 | WO2004020459A3 Secreted proteins |
| 03/30/2006 | WO2003014294A3 Tacis and br3 polypeptides and uses thereof |
| 03/30/2006 | US20060069246 Tumor necrosis factor receptor related proteins Tango-63d and Tango-63e |
| 03/30/2006 | US20060069242 Neurotrophic factor receptor |
| 03/30/2006 | US20060069241 Endocytosing delivery vehicle for targeting drugs and antibodies to prostate and other tissues |
| 03/30/2006 | US20060069239 Epididymis-specific gene as potential contraceptive target |
| 03/30/2006 | US20060069161 mixtures of fibrates selected from bezafibrate, binifibrate, ciprofibrate, clinofibrate, clofibrate, etofibrate, fenofibrate or gemfibrozil, and diflunisal, a diflunisal analog, cinnamic acid or a cinnamic acid analog, used for treating diabetes, obesity and non-insulin dependent diabetes |
| 03/30/2006 | US20060069104 Neurotrophic factor production accelerator |
| 03/30/2006 | US20060069065 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
| 03/30/2006 | US20060069058 Beta-sheet breaker peptide analogs that inhibit beta-pleated sheet formation in amyloid beta-peptide |
| 03/30/2006 | US20060069054 Compositions and methods for the therapy and diagnosis of breast cancer |
| 03/30/2006 | US20060069038 Irreversible caspase-3 inhibitors as active site probes |
| 03/30/2006 | US20060069037 Peptide-containing alpha-ketoamide cysteine and serine protease inhibitors |
| 03/30/2006 | US20060069036 Treating an inflammatory skin disorder by topically applying to the affected skin areas an effective amount of high concentration (40-60%) reduced glutathione; alpha lipoic acid as adjuvant and carrier; antiinflammatory agents; antiallergens; psoriasis; eczema; seborrhea dematitus; roazcea; acne |
| 03/30/2006 | US20060069035 Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy |
| 03/30/2006 | US20060069034 Antipathogenic benzamide compounds |
| 03/30/2006 | US20060069033 Use of poly-amminopyrrolecarboxamides alone or in combination with a cyclodextrin in the prophylaxis and treatment of animal parasitosis |
| 03/30/2006 | US20060069032 Beta-endorphin activity in cosmetics and dermatology |
| 03/30/2006 | US20060069031 use of agonist of hypothalamic hormone, i.e. GnRH, for preparation to support luteal phase during infertility treatment of female mammals; pharmaceutical agent supports luteal phase after spontaneous ovulation or after stimulation of follicular growth triggering final follicular maturation and ovulation |
| 03/30/2006 | US20060069030 Apolipoprotein A1 mimetics and uses thereof |
| 03/30/2006 | US20060069029 Exendin analog formulations |
| 03/30/2006 | US20060069028 A carbamate or urea containing comopound is useful to treat angiogeneisis; methionine aminopeptidase 2 (MetAP-2) coupled to a peptide prevents the metabolic degradation of the angiogenesis inhibitor compound |
| 03/30/2006 | US20060069027 Inhibitors of hepatitis C virus |
| 03/30/2006 | US20060069026 composition of a peptide analogue of the carboxyl-terminal sequence of a growth hormone, particularly an analogue of the carboxyl-terminal sequence of human growth hormone containing amino acid residues 177-191; including cyclic peptides, or acid addition salts |
| 03/30/2006 | US20060069025 Survivin, a protein that inhibits cellular apoptosis, and its modulation |
| 03/30/2006 | US20060069024 Plant PR-5 proteins as mammalian therapeutic agents |
| 03/30/2006 | US20060069023 Animal model for studying hormone signalling and method of modulating the signalling |
| 03/30/2006 | US20060069022 D-isomers of antimicrobial peptide |
| 03/30/2006 | US20060069021 Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs |
| 03/30/2006 | US20060069020 Preventing or reducing blood loss, cerebral ischemia or the onset of systemic inflammatory response associated with a surgical procedure by administering a non-naturally occurring kallikrein inhibitor polypeptide in combination with an anti-thrombolytic agent |
| 03/30/2006 | US20060069019 Crystal structure of the complex of hepatocyte growth factor beta chain with Met receptor and methods of use |
| 03/30/2006 | US20060069018 Treating lung diseases selected from acute pneumonia, pulmonary fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), and asthma by administering (E)-[5-[2-[1-phenyl-1-(3-pyridyl)methylideneaminoxy]ethyl]-7,8-dihydronaphthalen-1-yloxy]acetic acid or a salt thereof |
| 03/30/2006 | US20060069017 Somatostatin analog and uses thereof |
| 03/30/2006 | US20060069016 Immunosupressant carbon-carbon triple bond on the side chain of the position one amino acid : ocular allergy, dry eye, autoimmune and chronic inflammatory diseases, asthma, rheumatoid arthritis, multiple sclerosis, psoriasis, ulcerative colitis |
| 03/30/2006 | US20060069015 Immunosuppressive agent; novel cyclosporin derivatives chemically modified from cyclosporin A; chemically modified side chain at the position one amino acid and optionally a substitution at the position three amino acid of cyclosporin A; ocular allergy, dry eye, autoimmune, chronic inflammatory diseases |
| 03/30/2006 | US20060069014 Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
| 03/30/2006 | US20060069013 Pharmaceutical preparations comprising acid-stabilised insulin |
| 03/30/2006 | US20060069012 Methods and compositions for treating plasticity in a subject |
| 03/30/2006 | US20060069011 Method for treatment and repair of meniscal injuries |
| 03/30/2006 | US20060069010 Detoxification depot for Alzheimer's disease |
| 03/30/2006 | US20060069009 Treatment of neurological deficits in the striatum or substanta nigra pars compacta |
| 03/30/2006 | US20060069008 Using growth differentiation factor 5 (GDF5) to differentiate postpartum cells to dopaminergic phenotypes; tissue engineering and repair; regenerative medicine |
| 03/30/2006 | US20060068480 Polypeptides and polypeptide analogues |
| 03/30/2006 | US20060068472 Compositions to ameliorate protein misfolding and aggregation |
| 03/30/2006 | US20060068471 Soluble zcytor 11 cytokine receptors |
| 03/30/2006 | US20060068468 for modulating growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuron; comprising an altered Growth differentiation factor 11 (GDF11)-binding domain of an ActRII receptor |
| 03/30/2006 | US20060068464 Regulation of human g protein coupled receptor |
| 03/30/2006 | US20060068463 Natural killer cell activating factor ii |
| 03/30/2006 | US20060068453 Survivin, a protein that inhibits cellular apoptosis, and its modulation |
| 03/30/2006 | US20060068442 immunogens; tumor antigens; devoid of immunosuppressive domain; fusion proteins; immunotherapy |
| 03/30/2006 | US20060068441 Alternative pol kappa nucleotide and amino acid sequence and methods for using |
| 03/30/2006 | US20060068439 Ucp4 |
| 03/30/2006 | US20060068438 Identification of gene expression alterations underlying the aging process in mammals |